Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. Am J Nephrol. 2021;52(9):693–701.

Article  CAS  PubMed  Google Scholar 

Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(12):2311–6.

Article  CAS  PubMed  Google Scholar 

Chang SF, Chang PY, Chou YC, Lu SC. Electronegative LDL Induces M1 Polarization of Human Macrophages Through a LOX-1-Dependent Pathway. Inflammation. 2020;43(4):1524–35.

Article  CAS  PubMed  Google Scholar 

Yang TC, Chang PY, Lu SC. L5-LDL from ST-elevation myocardial infarction patients induces IL-1beta production via LOX-1 and NLRP3 inflammasome activation in macrophages. Am J Physiol Heart Circ Physiol. 2017;312(2):H265–74.

Article  PubMed  Google Scholar 

Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996;124(2):261–71.

Article  CAS  PubMed  Google Scholar 

Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS ONE. 2020;15(11):e0241993.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chu M, Wang AY, Chan IH, Chui SH, Lam CW. Serum small-dense LDL abnormalities in chronic renal disease patients. Br J Biomed Sci. 2012;69(3):99–102.

Article  CAS  PubMed  Google Scholar 

Shen H, Xu Y, Lu J, Ma C, Zhou Y, Li Q, et al. Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients. BMC Nephrol. 2016;17(1):143.

Article  PubMed  PubMed Central  Google Scholar 

Elias-Lopez D, Vedel-Krogh S, Kobylecki CJ, Wadstrom BN, Nordestgaard BG. Impaired Renal Function With Higher Remnant Cholesterol Related to Risk of Atherosclerotic Cardiovascular Disease: A Cohort Study. Arterioscler Thromb Vasc Biol. 2024;44(12):2647–58.

Article  CAS  PubMed  Google Scholar 

Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, et al. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clin J Am Soc Nephrol: CJASN. 2020;15(1):47–60.

Article  CAS  PubMed  Google Scholar 

Soohoo M, Hashemi L, Hsiung JT, Moradi H, Budoff MJ, Kovesdy CP, et al. Risk of atherosclerotic cardiovascular disease and nonatherosclerotic cardiovascular disease hospitalizations for triglycerides across chronic kidney disease stages among 2.9 million US veterans. J Am Heart Assoc. 2021;10(23):e022988.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692–711.

Article  CAS  PubMed  Google Scholar 

Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59(4):577–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bermudez-Lopez M, Forne C, Amigo N, Bozic M, Arroyo D, Bretones T, et al. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. Expert Opin Ther Targets. 2019;23(7):619–30.

Article  PubMed  Google Scholar 

Pantelidis P, Oikonomou E, Lampsas S, Zakynthinos GE, Lysandrou A, Kalogeras K, et al. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res. 2023;119(8):1641–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules. 2023;28(3):969.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bajaj A, Damrauer SM, Anderson AH, Xie D, Budoff MJ, Go AS, et al. Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). Arterioscler Thromb Vasc Biol. 2017;37(10):1971–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gruber I, Kollerits B, Forer L, Di Maio S, Schachtl-Riess JF, Kheirkhah A, et al. Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the german chronic kidney disease study. J Intern Med. 2024;296(6):510–26.

Article  CAS  PubMed  Google Scholar 

Barbagelata L, Masson W, Corral P, Lavalle-Cobo A, Nogueira JP, Rosa DG. Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies. J Nephrol. 2023;36(6):1549–59.

Article  PubMed  Google Scholar 

Jiang Y, Zhu X, Jordan K, Li Y, Conley S, Tang H, et al. Dyslipidemia-induced renal fibrosis related to ferroptosis and endoplasmic reticulum stress. J Lipid Res. 2024;65(9):100610.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seki M, Nakano T, Tanaka S, Kitamura H, Hiyamuta H, Ninomiya T, et al. Associations between the serum triglyceride level and kidney outcome in patients with chronic kidney disease: the fukuoka kidney disease registry study. J Atheroscler Thromb. 2024;31(11):1556–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weon B, Jang Y, Jo J, Jin W, Ha S, Ko A, et al. Association between dyslipidemia and the risk of incident chronic kidney disease affected by genetic susceptibility: Polygenic risk score analysis. PLoS ONE. 2024;19(4):e0299605.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jang SY, Kang M, Song E, Jang A, Choi KM, Baik SH, et al. Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study. Diabetes Res Clin Pract. 2024;210:111639.

Article  CAS  PubMed  Google Scholar 

Jung HN, Huh JH, Roh E, Han KD, Kang JG, Lee SJ, et al. High remnant-cholesterol levels increase the risk for end-stage renal disease: a nationwide, population-based, cohort study. Lipids Health Dis. 2024;23(1):165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bay Simony S, Rorbaek Kamstrup P, Bodtker Mortensen M, Afzal S, Gronne Nordestgaard B, Langsted A. High Lipoprotein(a) as a Cause of Kidney Disease: A Population-Based Mendelian Randomization Study. J Am Coll Cardiol. 2024;84(24):2407–10.

Article  CAS  PubMed  Google Scholar 

Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol. 2011;34(3):195–202.

Article  CAS  PubMed  Google Scholar 

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448–54.

Article  CAS  PubMed  Google Scholar 

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53(5):741–50.